Expand MIRA Menu
MIRA MENU

MIRA Latest Press Releases

-- October 24, 2025 --

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication ACCESS Newswire 7:30 AM

-- October 16, 2025 --

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain ACCESS Newswire 7:30 AM

-- September 30, 2025 --

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction ACCESS Newswire 7:30 AM

-- September 22, 2025 --

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog ACCESS Newswire 8:00 AM

-- September 16, 2025 --

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals ACCESS Newswire 7:30 AM

-- September 12, 2025 --

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation ACCESS Newswire 7:30 AM

-- August 19, 2025 --

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage ACCESS Newswire 8:30 AM

-- August 12, 2025 --

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin ACCESS Newswire 8:30 AM

-- July 30, 2025 --

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study ACCESS Newswire 7:30 AM

-- July 29, 2025 --

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain ACCESS Newswire 7:30 AM
Market Data Delayed 15 Minutes